PT - JOURNAL ARTICLE AU - Anahita Davoudi AU - Hegler Tissot AU - Abigail Doucette AU - Peter E. Gabriel AU - Ravi Parikh AU - Danielle L. Mowery AU - Stephen Miranda TI - Using Natural Language Processing to Classify Serious Illness Communication with Oncology Patients AID - 10.1101/2021.08.20.21262082 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.20.21262082 4099 - http://medrxiv.org/content/early/2021/08/22/2021.08.20.21262082.short 4100 - http://medrxiv.org/content/early/2021/08/22/2021.08.20.21262082.full AB - One core measure of healthcare quality set forth by the Institute of Medicine is whether care decisions match patient goals. High-quality “serious illness communication” about patient goals and prognosis is required to support patient-centered decision-making, however current methods are not sensitive enough to measure the quality of this communication or determine whether care delivered matches patient priorities. Natural language processing (NLP) offers an efficient method for identification and evaluation of documented serious illness communication, which could serve as the basis for future quality metrics in oncology and other forms of serious illness. In this study, we trained NLP algorithms to identify and characterize serious illness communication with oncology patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partially supported by Dr. Mowery's start-up funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Pennsylvania Institutional Review Board, protocol #842930.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset is not available.